CCR2 and arthritic joint disease: This is supported by older data showing that treatment of severe RA with leukapheresis efficiently removed blood monocytes concomitant with a clinical response (189), and that depleting CCR2+ monocytes using anti-CCR2 mAb could ameliorate collagen-induced arthritis, although the effects were dependent on the dose of mAb used (190).